Roivant Sciences Ltd.: Form 10-K for the period ended Mar 31, 2024
Filed with the SEC on May 30, 2024 and accepted by EDGAR at May 30, 2024, 16:46 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2023-04-01 to 2024-03-31 | $124.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2023-04-01 to 2024-03-31 | $501.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2023-04-01 to 2024-03-31 | $687.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2023-04-01 to 2024-03-31 | $4.24bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2023-04-01 to 2024-03-31 | $34.8m | us-gaap:InterestExpense |
| Income tax | 12 months2023-04-01 to 2024-03-31 | $22.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-04-01 to 2024-03-31 | $4.35bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-04-01 to 2024-03-31 | $5.23 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-04-01 to 2024-03-31 | $5.55 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-04-01 to 2024-03-31 | 831,049,444 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-04-01 to 2024-03-31 | −$765.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-04-01 to 2024-03-31 | $1.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-03-31 | $6.54bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $6.73bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $7.22bn | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $266.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $774.0m | us-gaap:Liabilities |
| Long-term debt | At period end2024-03-31 | $430.6m | us-gaap:LongTermDebt |
| Current portion of debt | At period end2024-03-31 | $12.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-03-31 | $5.97bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001140361-24-028145. Last ingested by Listed: Nov 3, 2026, 20:10 ET. Listed shows no prices and gives no investment advice.